Professional Documents
Culture Documents
Psychiatry
Guided by – Dr. Rahul Mathur
Assistant Professor
MGM Medical College Indore
Consultee
Therapeutic
Patient
Team
Basics
• The basic aim of C-L Psychiatry is to integrate the
information so as to provide optimal health care to
patient and effective liaison with patient, consultee
and team.
GENERAL PRINCIPLES
Don’t experiment
unnecessarily
Be simple in Mono drug and
with drugs in
liaison psychiatry lower doses help.
medically sick
patients.
Common Conditions
Common Conditions
• Delirium
• Suicide
• Depression
• Agitation
• Hepatic Impairment
• Renal Impairment
• Cardiac Conditions
• HIV
• TB
• Fitness for surgery
Common Conditions
• Among the three most common psychiatric syndromes seen in
CLP setting, delirium figured as one of the three most common
diagnoses among 79 (87.8%) institutes, and this was followed by
substance use disorders (70%), self‑harm (60%), and depression
(38.9%). (Grover et al)
• The referral rate was found to be a meagre 1.1% which is too little
compared to incidence of psychiatric morbidities found in general
hospitals ranging from 18.8% to as high as 94.4%. (Grover et al)
Delirium
• Delirium is a transient organic mental syndrome of acute onset ,
characterized by global impairment of cognitive functions, a
reduced level of consciousness, attentional abnormalities,
increased or decreased psychomotor activity and a disordered
sleep wake cycle.
Hepatic
Impairment
Reduced Reduced
ability to capacity to
synthesise metabolise
Hepatic Impairment – General
Principles
• Prescribe as few drugs as possible.
• Lower starting doses
• Leave longer intervals between dosage increases
• cautious with drugs that are extensively hepatically
metabolized
• Avoid medicines with a long half-life
• Avoid drugs that are very sedative
• Avoid drugs that are very constipating
• Avoid drugs that are known to be hepatotoxic
Hepatic Impairment –
Antipsychotics
• Amisulpiride – Renal Excretion. No dose reduction
required.
• Aripiprazole – Extensively hepatic metabolism. Caution!
• Clozapine - Very sedative and constipating.
Contraindicated in active liver disease associated with
nausea, anorexia or jaundice, progressive liver disease
or hepatic failure.
• Flupenthixol/Zuclopenthixol - Both are extensively
hepatically metabolised. Caution! Depot best avoided.
• Haloperidol – Caution in liver disease!
Hepatic Impairment –
Antipsychotics
• Olanzapine - Although extensively hepatically
metabolised. Sedative and Constipating – Caution
advised!
• Quetiapine – Hepatic metabolism. Caution advised!
Start at lower dose.
• Risperidone – Extensive hepatic metabolism. Half
starting dose. If severe impairment, start 0.5mg BD
and increase at a maximum of 0.5mg bd.
Hepatic Impairment
• – Antidepressants
• All SSRIs are hepatically metabolised. May accumulate on
chronic dosing. Dose reduction is required (upto 50%).
Sertraline is preferred.
• All TCAs are hepatically metabolised and have high protein
binding.
• – Mood Stabilizers
• Dose reduction of all mood stabilisers by upto 50% with slow
titration and close monitoring of LFT.
• No dose reduction required with lithium.
Hepatic Impairment
• Benzodiazepines : Lorazepam, oxazepam,
temazepam considered to be safe.
Renal Impairment – General
Principles
• Be cautious when using drugs that are extensively renally
cleared (e.g. sulpiride, amisulpride, lithium).
• Start at a low dose and increase slowly because, in renal
impairment, the half‐life of a drug and the time for it to reach
steady state are often prolonged. Plasma level monitoring
may be useful for some drugs.
• Try to avoid long‐acting drugs (e.g. depot preparations). Their
dose and frequency cannot be easily adjusted should renal
function change.
• Prescribe as few drugs as possible. Patients with renal failure
take many medications requiring regular review. Interactions
and adverse effects can be avoided if fewer drugs are used.
Renal Impairment
• No antipsychotic clearly preferred over other.
• Sulpiride and Amisulpiride avoided
• Anticholinergic drugs to be avoided.
• FGA - haloperidol 2–6 mg/day
• SGA – Olanzapine – 5mg/day
Zidovudine Bone marrow suppression Concurrent use with certain psychotropics (e.g.
clozapine) may increase the risk of
myelosuppression/neutropenia
Tenofovir Reduces bone mineral density May compound the reductions in bone mineral
density possible with prolactin‐elevating
antipsychotics
Darunavir, efavirenz, maraviroc, ritonavir, Seizure(s) May increase seizure risk associated with certain
saquinavir, zidovudine psychotropic drugs
All combination antiretroviral drugs Metabolic abnormalities risk of metabolic adverse effects associated with
certain psychotropic drugs
Atazanavir, darunavir, efavirenz, lopinavir, ECG changes May increase risk of arrhythmias associated
rilpivirine, ritonavir, with
Saquinavir certain psychotropic drug
Prescribing in TB patients
• Isoniazid, Ethambutol, Rifampicin, Cycloserine, 2nd
generation FQs, are known to cause psychiatric
disorders.
• Also various anti-tubercular drugs are known to
have multiple interactions with psychotropics.
• Hence Caution is advised while prescribing to
tubercular patients.
Prescribing in TB patients
Isoniazid Causes MAO inhibition May interact with SSRIs and TCAs theoretically
increasing risk of serotonin syndrome.
Anticonvulsants CNS depressant activity may reduce anaesthetic Probably, usually continued for people with
requirement epilepsy
Antidepressants – SSRIs Danger of serotonin syndrome if administered Probably, but avoid other serotonergic agents
with pethidine, fentanyl, pentazocine or
tramadol
Occasional seizures reported
Rule out hyponatremia in all surgical patient
Psychiatric medications and
surgery
Drug class Consideration Safety in surgery
Antidepressants – TCAs Danger of serotonin syndrome (clomipramine, Unclear, but anaesthetic agents need to be
amitriptyline) if administered with pethidine, carefully chosen
pentazocine or tramadol
Many drugs prolong QT interval so arrhythmia
more likely
Antipsychotic Most drugs lower seizure threshold Probably, usually continued to avoid relapse
Increased risk of arrhythmia
Benzodiazepines Reduced requirements for induction and Probably; usually continued
maintenance anesthetics
Take Home Message
• Over the years Consultation-Liaison (C-L) psychiatry has
contributed significantly to the growth of the psychiatry
and has brought psychiatry very close to the advances in
the medicine.
• C-L psychiatrist should have adequate knowledge of
mental and physical illnesses as well as how they affect
each other.
• And should know how various drugs and diseases interact
with psychotropics with special regards to their safety.
• C-L psychiatrist must look at the complete picture while
providing services to the general hospitals.
References
• Lipowski, Z., 1983. Current Trends in Consultation-Liaison Psychiatry*. The Canadian Journal of
Psychiatry, 28(5), pp.329-338.
• Grover S. State of consultation-liaison psychiatry in India: Current status and vision for future. Indian J
Psychiatry 2011;53:202-13
• Grover S, Avasthi A. Consultation-liaison psychiatry services: A survey of medical institutes in India.
Indian J Psychiatry 2018;60:300-6
• Mudgal V, Rastogi P, Niranjan V, et al. Pattern, clinical and demographic profile of inpatient psychiatry
referrals in a tertiary care teaching hospital: a descriptive study. General Psychiatry 2020;33:e100177.
doi:10.1136/ gpsych-2019-100177
• Taylor, D., Paton, C. and Kerwin, R., 2018. The Maudsley Prescribing Guidelines. 13th ed. Wiley
Blackwell.
• Sadock, B., Sadock, V. and Ruiz, P., 2009. Kaplan & Saddock's comprehensive textbook of
psychiatry, volume 1 and 2. Philadelphia: Lippincott Williams and Wilkins.
• Shah SU, Iqbal Z, White A, et al Heart and mind: (2) psychotropic and cardiovascular therapeutics
Postgraduate Medical Journal 2005;81:33-40.
• Doherty, A., Kelly, J., McDonald, C., O’Dywer, A., Keane, J. and Cooney, J., 2013. A review of the
interplay between tuberculosis and mental health. General Hospital Psychiatry, 35(4), pp.398-406.
• Alexander, T. and Bloch, S., 2002. The Written Report in Consultation–Liaison Psychiatry: A Proposed Schema.
Australian & New Zealand Journal of Psychiatry, 36(2), pp.251-258.
Appendix –Proforma for CLP
Thank You